Katherine Hu1,2, Zhaowen Zhu1,2, Meleah M Mathahs1,2, Huy Tran1,2, Jerry Bommer3,4, Charles A Testa5, Warren N Schmidt1,2. 1. Department of Internal Medicine and Research Service, Veterans Affairs Medical Center, Iowa City, IA 52246, USA. 2. Department of Internal Medicine of the Roy G. And Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA. 3. Frontier Scientific, Logan, UT 84321, USA. 4. Echelon Biosciences Inc, Salt Lake City, UT 84108, USA. 5. Curza, Provo, UT and Cambridge, MA, USA.
Abstract
BACKGROUND: Antiviral actions of tetrapyrroles have been described in a number of systems. Our goal was to evaluate antagonism of the HCV NS3-4A protease by a variety of common porphyrins and characterize structure-activity relationships that may be useful for future drug design of HCV and related Flaviviruses. METHODS: Using fluorometric assays, common metalloprotoporphyrins (MPP) all inhibited NS3-4A protease with IC50 values in low micromolar ranges [CoPP (1.4 µM) < ZnPP = MnPP = SnPP < CuPP < FePP (6.5 µM) = protoporphyrin]. RESULTS: Lineweaver-Burk plots confirmed that MPP: NS3 inhibition was basically competitive. All tested MPPs inhibited HCV genotype 1A, 1B, 2A and 3A recombinant proteases with the same fidelity suggesting wide antagonistic capabilities. However, when the MPPs were tested in cellular incubations with HCV replicons only Zn, Fe and free-base protoporphyrin showed comparable EC50 and IC50 values suggesting that there may be critical differences in MPP uptake and intracellular availability. Meso, deutero, and isohematoporphyrin derivatives, with or without metal substitution, all showed less anti-protease and antiviral activities as compared to protoporphyrins, suggesting that the planar, vinyl side chains are important for protease active site binding. MPPs were also active against three common protease mutants (T54A, A156T, and V36M) with equivalent or better IC50 values as compared to wild type enzyme. CONCLUSION: These findings document the versatility of MPPs as antiviral agents with an expanded sensitivity for HCV genotypes and resistance to some common viral mutations. The results also suggest that further study of MPP structure and function will be useful for the development of new antiviral agents.
BACKGROUND: Antiviral actions of tetrapyrroles have been described in a number of systems. Our goal was to evaluate antagonism of the HCV NS3-4A protease by a variety of common porphyrins and characterize structure-activity relationships that may be useful for future drug design of HCV and related Flaviviruses. METHODS: Using fluorometric assays, common metalloprotoporphyrins (MPP) all inhibited NS3-4A protease with IC50 values in low micromolar ranges [CoPP (1.4 µM) < ZnPP = MnPP = SnPP < CuPP < FePP (6.5 µM) = protoporphyrin]. RESULTS: Lineweaver-Burk plots confirmed that MPP: NS3 inhibition was basically competitive. All tested MPPs inhibited HCV genotype 1A, 1B, 2A and 3A recombinant proteases with the same fidelity suggesting wide antagonistic capabilities. However, when the MPPs were tested in cellular incubations with HCV replicons only Zn, Fe and free-base protoporphyrin showed comparable EC50 and IC50 values suggesting that there may be critical differences in MPP uptake and intracellular availability. Meso, deutero, and isohematoporphyrin derivatives, with or without metal substitution, all showed less anti-protease and antiviral activities as compared to protoporphyrins, suggesting that the planar, vinyl side chains are important for protease active site binding. MPPs were also active against three common protease mutants (T54A, A156T, and V36M) with equivalent or better IC50 values as compared to wild type enzyme. CONCLUSION: These findings document the versatility of MPPs as antiviral agents with an expanded sensitivity for HCV genotypes and resistance to some common viral mutations. The results also suggest that further study of MPP structure and function will be useful for the development of new antiviral agents.
Authors: Kenneth E Sherman; Steven L Flamm; Nezam H Afdhal; David R Nelson; Mark S Sulkowski; Gregory T Everson; Michael W Fried; Michael Adler; Hendrik W Reesink; Marie Martin; Abdul J Sankoh; Nathalie Adda; Robert S Kauffman; Shelley George; Christopher I Wright; Fred Poordad Journal: N Engl J Med Date: 2011-09-15 Impact factor: 91.245
Authors: Yutong Jiang; Steven W Andrews; Kevin R Condroski; Brad Buckman; Vlad Serebryany; Steve Wenglowsky; April L Kennedy; Machender R Madduru; Bin Wang; Michael Lyon; George A Doherty; Benjamin T Woodard; Christine Lemieux; Mary Geck Do; Hailong Zhang; Joshua Ballard; Guy Vigers; Barbra J Brandhuber; Peter Stengel; John A Josey; Leonid Beigelman; Lawrence Blatt; Scott D Seiwert Journal: J Med Chem Date: 2013-05-28 Impact factor: 7.446
Authors: Ulrike Protzer; Stefan Seyfried; Maria Quasdorff; Gabriele Sass; Miriam Svorcova; Dennis Webb; Felix Bohne; Marianna Hösel; Peter Schirmacher; Gisa Tiegs Journal: Gastroenterology Date: 2007-07-25 Impact factor: 22.682
Authors: Carine Fillebeen; Ana Maria Rivas-Estilla; Martin Bisaillon; Prem Ponka; Martina Muckenthaler; Matthias W Hentze; Antonis E Koromilas; Kostas Pantopoulos Journal: J Biol Chem Date: 2005-01-06 Impact factor: 5.157
Authors: Zhaowen Zhu; Huy Tran; Meleah M Mathahs; Brian D Fink; John A Albert; Thomas O Moninger; Jeffery L Meier; Ming Li; Warren N Schmidt Journal: Pharmacol Res Perspect Date: 2021-12